Search results
2 cze 2022 · Conclusions: On average, we found a man undergoing radical prostatectomy for localized prostate cancer can expect about a 1 in 4 chance of biochemical recurrence. Of men with BCR, we identified a 1 in 10 chance of developing metastases, surviving nearly 9 years after incident metastasis.
11 mar 2023 · Panel A shows the probability of survival from prostate cancer among the trial patients in the active-monitoring group, the prostatectomy group, and the radiotherapy group over the years.
10 mar 2020 · In patients with truly long-term follow-up after prostatectomy for prostate cancer, the risk of metastatic disease and cancer death is very low. Patients with the lower risk findings do not appear to benefit from routine follow-up after 10 years free of biochemical recurrence.
To evaluate long-term outcomes of patients with high Gleason sum (8–10) at radical prostatectomy (RP) and to identify predictors of prostate cancer-specific survival (CSS) in this cohort. Methods.
10 maj 2021 · The safety of active surveillance (AS) in favorable intermediate-risk (FIR) prostate cancer (PCa) remains uncertain. To provide guidance on clinical decision-making, we examined long-term and pathological outcomes of low-risk and intermediate-risk PCa patients after radical prostatectomy (RP).
Results from nonrandomized trials should be interpret with caution, but even after careful risk adjustment, survival rates for men with higher-risk cancer appeared to be highest for patients whose first treatment was surgery rather than radiotherapy, hormones, or monitoring. Keywords. Active surveillance. Androgen deprivation therapy.
For example, if the 5-year relative survival rate for a specific stage of nasal cavity (nose) or paranasal sinus cancer is 80%, it means that people who have that cancer are, on average, about 80% as likely as people who don’t have that cancer to live for at least 5 years after being diagnosed.
